Bacteriocins from Limosilactobacillus and Ligilactobacillus: ecological logic, mechanistic diversity, and translational potential in the post-Lactobacillus taxonomy
Frontiers in Microbiology · 15.07.2026 · 17
DOI: 10.3389/fmicb.2026.1875597 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 15.07.2026. Verfasst von Samson Baranzan Wayah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Environmental, Life, Natural Science, and Technology, Okayama University, Okayama, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Bacteriocins are ribosomally synthesized antimicrobial peptides that contribute to microbial competition, niche establishment, and community structure. The 2020 taxonomic reorganization of the former broad Lactobacillus genus provides a useful framework for reinterpreting bacteriocin diversity in lineage-specific ecological contexts. This review focuses on bacteriocins produced by species now assigned to Limosilactobacillus and Ligilactobacillus , two host- and food-associated genera that include several reported bacteriocin producers. These genera were selected because they contain bacteriocins with diverse structural features, including cyclic peptides, class IIa and IIb peptides, class IId peptides, defensin-like peptides, and larger proteinaceous bacteriocins, and because many producer strains originate from competitive ecological niches such as the gastrointestinal tract, oral cavity, vagina, milk, poultry, livestock, and fermented foods. We synthesize evidence on bacteriocin biosynthetic gene clusters, molecular diversity, antimicrobial mechanisms, ecological functions, physicochemical stability, and translational potential. This review also distinguishes bacteriocin-specific evidence from effects attributable to bacteriocin-producing strains, particularly for immunomodulation, co-aggregation, pathogen exclusion, and microbiota modulation. Finally, we address how comparative genomics, structured genome mining and artificial intelligence-aided prediction can speed bacteriocin discovery, emphasizing the necessity of experimental validation, standardized activity assays, safety evaluation and scalable production. This study gives a systematic framework to understand the bacteriocins of Limosilactobacillus and Ligilactobacillus in the post- Lactobacillus era by integrating taxonomy, ecology, mechanism and translational evidence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate School of Environmental, Life, Natural Science, and Technology, Okayama University, Okayama, Japan.
- Department of Biochemistry, Faculty of Life Sciences, Kaduna State University, Kaduna, Nigeria.
- Institute of Ocean and Earth Sciences, University of Malaya, Kuala Lumpur, Malaysia.
- Faculty of Medicine, Nursing and Health Sciences, SEGi University, Kuala Lumpur, Malaysia.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Wayah, S. B., Arakawa, K., & Philip, K. (2026). Bacteriocins from Limosilactobacillus and Ligilactobacillus: ecological logic, mechanistic diversity, and translational potential in the post-Lactobacillus taxonomy. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1875597
Vancouver
Wayah SB, Arakawa K, Philip K. Bacteriocins from Limosilactobacillus and Ligilactobacillus: ecological logic, mechanistic diversity, and translational potential in the post-Lactobacillus taxonomy. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1875597
BibTeX
@article{Wayah2026,
author = {Wayah, Samson Baranzan and Arakawa, Kensuke and Philip, Koshy},
title = {Bacteriocins from Limosilactobacillus and Ligilactobacillus: ecological logic, mechanistic diversity, and translational potential in the post-Lactobacillus taxonomy},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1875597}
}
EUVIMED